Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BrainStorm Cell Therapeutics privately nets $9.7mm

Executive Summary

BrainStorm Cell Therapeutics Inc. (autologous stem cell therapeutics for neurodegenerative diseases) netted $9.7mm by selling 42mm shares at $0.25 (a 17% discount) to private investors, including some health care-focused funds. Buyers also received three-year warrants to purchase 42mm shares for $0.35.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Biotech
    • Private Placement

Related Companies